Ovid Therapeutics' candidate OV329 targets GABA aminotransferase, amidst general FDA approval news for biotech stocks.
1 report, 0 independent
Updated Jun 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ovid Therapeutics' candidate OV329 targets GABA aminotransferase, amidst general FDA approval news for biotech stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ovid Therapeutics (United States)
company in New York, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet